An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma

被引：0
|
作者：
Shepard, Dale Randall
Ahmed, Muneeb
Bekaii-Saab, Tanios S.
Wolff, Johannes
机构：
[1] Cleveland Clin, Cleveland, OH USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA USA
[3] Mayo Clin, Phoenix, AZ USA
[4] Replimune Inc, Woburn, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3628
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multicenter, phase II trial
    Xu, J.
    Shen, J.
    Gu, S.
    Zhang, Y.
    Wu, L.
    Wu, J.
    Shao, G.
    Zhang, Y.
    Xu, L.
    Yin, T.
    Liu, J.
    Ren, Z.
    Xiong, J.
    Mao, X.
    Zhang, L.
    Yang, J.
    Li, L.
    Chen, X.
    Wang, Z.
    Wang, Q.
    ANNALS OF ONCOLOGY, 2020, 31 : S689 - S689
  • [32] Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
    Kerr, Rachel S.
    Love, Sharon
    Segelov, Eva
    Johnstone, Elaine
    Falcon, Beverly
    Hewett, Peter
    Weaver, Andrew
    Church, David
    Scudder, Claire
    Pearson, Sarah
    Julier, Patrick
    Pezzella, Francesco
    Tomlinson, Ian
    Domingo, Enric
    Kerr, David J.
    LANCET ONCOLOGY, 2016, 17 (11): : 1543 - 1557
  • [33] Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
    Galle, Peter R.
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Zhu, Andrew X.
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Mulla, Sohail
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Ding, Beiying
    Liu, Juan
    Huang, Chen
    Lim, Ho Yeong
    Cheng, Ann-Lii
    Ducreux, Michel
    LANCET ONCOLOGY, 2021, 22 (07): : 991 - 1001
  • [34] Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial
    Kelley, Robin Kate
    Rimassa, Lorenza
    Cheng, Ann-Lii
    Kaseb, Ahmed
    Qin, Shukui
    Zhu, Andrew X.
    Chan, Stephen L.
    Melkadze, Tamar
    Sukeepaisarnjaroen, Wattana
    Breder, Valery
    Verset, Gontran
    Gane, Edward
    Borbath, Ivan
    Rangel, Jose David Gomez
    Ryoo, Baek-Yeol
    Makharadze, Tamta
    Merle, Philippe
    Benzaghou, Fawzi
    Banerjee, Kamalika
    Hazra, Saswati
    Fawcett, Jonathan
    Yau, Thomas
    LANCET ONCOLOGY, 2022, 23 (08): : 995 - 1008
  • [35] Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis:: Safety and efficacy in an open-label clinical trial
    Antoni, CE
    Nüsslein, HG
    Wollenhaupt, J
    Burmester, GR
    Krüger, K
    Kalden, JR
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 276 - 276
  • [36] Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial
    Kalden, J. R.
    Nuesslein, H. G.
    Wollenhaupt, J.
    Burmester, G. -R.
    Krueger, K.
    Antoni, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (05) : 834 - 840
  • [37] First-line Treatment for advanced Renal Cell Carcinoma A Phase 3, open-label, randomized Study of Atezolizumab (Anti-PD-L1-Antibody) in Combination with Bevacizumab versus Sunitinib in Patients with untreated advanced Renal Cell Carcinoma ("IMmotion") AN 37/15 of AUO
    Rexer, H.
    Doehn, C.
    UROLOGE, 2016, 55 (09): : 1242 - 1243
  • [38] The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study
    Yi, L.
    Ning, Z.
    Xu, L.
    Shen, Y.
    Zhu, X.
    Yu, W.
    Xie, J.
    Meng, Z.
    ESMO OPEN, 2024, 9 (02)
  • [39] Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
    Rini, Brian I.
    Powles, Thomas
    Atkins, Michael B.
    Escudier, Bernard
    McDermott, David F.
    Suarez, Cristina
    Bracarda, Sergio
    Stadler, Walter M.
    Donskov, Frede
    Lee, Jae Lyun
    Hawkins, Robert
    Ravaud, Alain
    Alekseev, Boris
    Staehler, Michael
    Uemura, Motohide
    De Giorgi, Ugo
    Mellado, Begona
    Porta, Camillo
    Melichar, Bohuslav
    Gurney, Howard
    Bedke, Jens
    Choueiri, Toni K.
    Parnis, Francis
    Khaznadar, Tarik
    Thobhani, Alpa
    Li, Shi
    Piault-Louis, Elisabeth
    Frantz, Gretchen
    Huseni, Mahrukh
    Schiff, Christina
    Green, Marjorie C.
    Motzer, Robert J.
    LANCET, 2019, 393 (10189): : 2404 - 2415
  • [40] Initial Results from an Open-Label, Multicenter, Phase 1b/2 Study of RP1 Oncolytic Immunotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Advanced Cutaneous Malignancies (ARTACUS)
    Migden, M. R.
    Chai-Ho, W.
    Daniels, G. A.
    Davar, D.
    Wise-Draper, T.
    Kheterpal, M.
    Tang, J. C.
    Bolotin, D.
    Verschraegen, C.
    Poklepovic, A.
    Tsai, K. K.
    Navia, S.
    Hou, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S1200 - S1200
12345